Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 Mg on Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response with Imatinib (PonaZero_study)

Por: Gutierrez, VG, Casado, LF, Ayala, R, Sanchez-Guijo, F, Boluda, JCH, Casares, MTG, Xicoy, B, Maestro, B, Steegmann, JL and de Diego, AG

---

Publicada: 13 nov 2019

---

---

Filiaciones:
Gutierrez, VG:
 Hosp Univ Ramon & Cajal, Hematol, Madrid, Spain

Casado, LF:
 Hosp Unversitario Virgen Salud, Toledo, Spain

Ayala, R:
 Hosp Univ 12 Octubre, Dept Hematol, CNIO, Madrid, Spain

Sanchez-Guijo, F:
 Univ Salamanca, IBSAL Hosp Univ Salamanca, Dept Hematol, CIC & CIBERONC, Salamanca, Spain

Boluda, JCH:
 Hosp Clin Univ, Valencia, Spain

Casares, MTG:
 Hosp Univ Gran Canaria Dr Negrin, Las Palmas Gran Canaria, Spain

:
 Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Josep Carreras Leukemia Res Inst, Badalona, Spain

Maestro, B:
 Fdn Teofilo Hernando, Madrid, Spain

Steegmann, JL:
 Hosp La Princesa, Madrid, Spain

de Diego, AG:
 Fdn Teofilo Hernando, Madrid, Spain